US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief ...

Gilead CEO Daniel O’Day has hired Berger away from Sanofi. Elsewhere, Lonza is reorganizing and Bausch + Lomb is exploring a ...

Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending seladelpar for the ...

Sciences announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive ...

Gilead Sciences names Sanofi's Dietmar Berger as new CMO, replacing Merdad Parsey amid challenging year marked by setbacks ...

Gilead Sciences, Inc. has announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical ...

Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...

(Reuters) -Gilead Sciences said on Thursday it has appointed Sanofi’s Dietmar Berger as its chief medical officer, replacing ...

IEA predicts oil surplus in 2025, but futures market remains bullish. Q4 2024 shows potential deficit. Read an analysis of ...

(RTTNews) - Gilead Sciences, Inc. (GILD) announced Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending ...

In a report released today, Asthika Goonewardene from Truist Financial assigned a Hold rating to Gilead Sciences (GILD – Research Report). The company’s shares closed yesterday at $92.38. Pick the ...

The report provides a comprehensive... 12 déc 2024 Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer ...